The James Webb Telescope: Viewing the Universe from Lagrange Point L2
To locate the second Lagrange point, L2, draw a line 150 million km from Sun to Earth and extend it by about one per cent.
Normally an object orbiting the Sun farther out than Earth takes longer than a year to complete a cycle. But at L2 the gravitational forces of Sun and Earth combine to speed things up, so a
spacecraft
placed there moves in synchrony with the Earth, all three objects remaining in a straight line. Keeping the object close to Earth allows for faster communications and higher data volumes.
Space telescopes
The Hubble Space Telescope has been orbiting Earth for 35 years and continues to provide remarkable images of space. Hubble has led to major breakthroughs in astronomy. It has enabled us to determine the accelerating expansion rate of the universe and pin down its age to about 13.7 billion years. Hubble should continue to operate for at least another decade.
READ MORE
It orbits at about 550km above the Earth's surface and much of the sky is eclipsed by the planet as the telescope moves in and out of Earth shadow every 90 minutes. On Christmas Day, 2021, a successor to Hubble, the James Webb Space Telescope (JWST or Webb), was launched. Unlike Hubble, Webb orbits the Sun about 1.5 million km beyond Earth at L2, providing an unimpeded view of the sky.
[
Life beyond our solar system? Scientists claim 'strongest evidence' so far
Opens in new window
]
[
Ireland's astronomical observatories to be put forward for international recognition from Unesco
Opens in new window
]
Webb observes in the infrared spectrum and can detect objects 100 times fainter than Hubble. Its main objectives are to study how the first galaxies formed and evolved after the Big Bang, the birth of stars and planetary systems and the origins of life.
Its mirror, with 18 hexagonal gold-plated segments, has a 6.5-metre diameter, considerably larger than that of the Hubble Space Telescope. The first image from Webb was revealed by US president
Joe Biden
in July 2022.
Location and orbit
An object placed exactly at the L2 Lagrange point would be permanently in the shadow of the Earth, cutting off the Sun as a source of power. So Webb has been placed in a halo orbit, following an elliptical path of width about 830,000km around the line from the Sun through L2, so that it avoids being eclipsed by either the Earth or Moon.
This ensures uninterrupted solar power and Earth communications on its sun-facing side. Its sun-shield is oriented so that the temperature of the spacecraft remains constant at a cool 50 Kelvin (minus 223 degrees), crucial for observation in the infrared spectrum.
Launching Webb to L2 was like cycling to the top of a hill by pedalling furiously at the beginning of the climb, generating enough speed to coast uphill and come to a halt near the top. Although an object placed at L2 is in equilibrium, the balance of forces is metastable and a small disturbance will cause it to gradually drift away into its own solar orbit and lose contact with Earth.
However, a spacecraft can be kept near L2 with minimal energy, remaining in line with Earth as it orbits the Sun. The telescope is not intended to be serviced in space but, with relatively little rocket thrust needed to keep it on station at L2, Webb should remain operational for 20 years or more.
Peter Lynch is emeritus professor at the School of Mathematics & Statistics, University College Dublin. He blogs
at
thatsmaths.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Irish Times
6 hours ago
- Irish Times
‘The way to a human's brain and immune system is through the gut'
There is an old saying, 'you are what you eat'. Now, more scientific evidence is emerging to show that our gastrointestinal system interacts with our nervous system. It seems our guts do indeed talk to our brains. In a recent post on his Substack Ground Truths, Dr Eric Topol describes the complex interplay involving the gut-brain axis. There are four principal interactions by which the gut influences the brain: through the nervous system; by means of hormones; through the immune system; and via the microbiome. The gut microbiome is the community of all the bacteria and viruses in our intestines. READ MORE 'The abundant and diverse bacteria in the gut microbiome [are made up] of tens of trillion cells of more than 3,000 species. These gut bacteria and their metabolites have an outsize impact by producing or stimulating different neurotransmitters and metabolites that communicate with the brain and the immune system,' Topol writes. In addition, cells in the gut produce hormones such as glucagon-like peptide (GLP-1), gastric inhibitory peptide (GIP), secretin, ghrelin and gastrin. The gut's interaction with the immune system is critical to maintaining the integrity of the gut lining and the blood-brain-barrier, Topol says. The gut microbiome has been described as the thermostat that controls the level of inflammation in our body. Every time we eat we contribute good and bad microbes to the microbiome. Illustration: Getty Images One way to think of the process is to compare it to taking oral medication. The microbes in our gut make compounds that enter our bloodstream, in the same way that when you take a pill by mouth, it makes its way through your blood system. Those compounds from our gut microbes are small enough to cross the blood-brain barrier and enter the brain, just like medications do. Research shows that microbes found in our gastrointestinal tract can have a direct impact on mood. In one Canadian study, researchers found that when 10- and 11-year-olds met recommendations for diet, as well as sleep, physical activity and screen time, they were less likely to need mental health interventions as adolescents. Conversely, separate research found that participants who had diets high in ultra-processed foods had the highest risk of depression. And we know that following a Mediterranean diet can prevent and reduce symptoms of depression and anxiety. There is also evidence of the microbiome's effect on our neurological health through the use of faecal transplants. This involves giving a small sample of stool from the colon of a healthy person to a recipient for therapeutic purposes. It is now a recognised treatment for recurrent bowel infection with the bacteria Clostridium difficile. The goal with the transplant is to have the healthy bacteria outcompete the Clostridium difficile and wipe out the stubborn infection. [ Dr Muiris Houston: Lifestyle changes to reduce your risk of stroke, dementia and late-life depression Opens in new window ] Studies are now under way looking at using faecal transplants for anorexia nervosa in teenagers. Research suggests there is a gut-brain connection, and scientists are finding there is an association between anorexia and imbalances in the gut microbiome, which could influence a person's behaviour. And there is a case report of a child with autism experiencing improvements in behaviour while being treated with faecal transplant for Clostridium difficile. The new GLP-1 family of drugs (such as Ozempic), developed for the treatment of diabetes and obesity, are now thought to influence the gut-brain axis. They are recognised for treating a broadening range of illnesses including heart failure, kidney disease, liver disease and sleep apnoea. Topol notes that even before there is weight loss with these drugs, there is evidence from experimental models of reduced body and brain inflammation. While drugs such as Ozempic have little direct penetrance to the brain, they exert their effect chiefly through the gut-brain axis. Topol speculates that, in time, the old saying, 'the way to a man's heart is through his stomach' will be revised to 'the way to a human's brain and immune system is through the gut'.
Irish Times
a day ago
- Irish Times
Austin Taylor: ‘I found it so fascinating and poignant how we portray women in the media, especially powerful women who make mistakes'
Austin Taylor is speaking to me from her parents' attic in the farmhouse where she grew up in rural Maine. The 26-year-old is the picture of vibrant youth – glowing skin, a long mane of thick blonde hair and an easy-going demeanour. She is about to begin a law degree at Stanford University and has already completed a double degree in chemistry and English at Harvard – they call it a double concentrator. She has also just published her debut novel, Notes On Infinity , which she sold in the US for a seven-figure sum. You could call her an over-achiever, but I'm not sure she'd agree. In fact, not too long ago, she felt like a failure. 'I certainly felt intense pressure at Harvard. You're surrounded by people doing incredible cutting-edge work, especially in the sciences. You're surrounded by the legacy of people who have come through the institution before you who have done incredible things. You're surrounded by professors who are doing amazing research and teaching, and your peers who have amazing ideas and are working on really cool stuff in addition to taking five classes a semester and doing really well. There's a sense that if you're not doing something absolutely incredible, you're falling short or failing. I certainly felt that way.' It's something she wanted to explore in Notes On Infinity, particularly around the 'move fast and break things' culture that exists at the nexus of scientific research and venture capital-funded biotech start-ups. The book tells the story of Zoe and Jack, two brilliant Harvard students whose breakthrough scientific discoveries prompt them to drop out and set up a biotech company that claims to have found the cure for ageing. It's a classic Icarus tale of young idealism warped by greed and ambition. 'The dollar amounts are just unimaginable,' she says of biotech VC funding, 'especially for really young people. I think the incentive structures that that amount of money creates are often problematic and scary, especially in science, because science is fundamentally such a slow, iterative, uncertain process and business, especially in pitching a start-up, is all about positive spin. And that's a fundamental tension. And sometimes that creates awesome innovation and other times it creates fire and broken glass and damage.' You can probably guess which of these paths her book follows. READ MORE [ Rethink needed on meeting the demand for Stem graduates Opens in new window ] The novel was somewhat inspired by the scandal surrounding Elizabeth Holmes and her blood-diagnostic start-up, Theranos. Holmes, a brilliant and beautiful scientist, was the face of the company but was eventually jailed for defrauding investors in a spectacular fall from grace. In Notes On Infinity, Taylor's protagonist Zoe is a beautiful, brilliant young woman who also becomes the face of her and Jack's start-up. 'One of the things I was interested in exploring was the obsession with women in [ Stem ] spaces and the tokenisation of women in these spaces. Elizabeth Holmes was lauded for her gender during Theranos's rise, then after its fall she was demonised for her gender. I heard a disturbing number of comments about how she must have used her sexuality to manipulate male funders. That fixation on gender and self-presentation and hair and clothes and make-up, I do think it's heightened by the fact that women are such a minority in science. Former Theranos chief executive Elizabeth Holmes leaving court in San Jose, California, in March 2023. Photograph: Jeff Chiu/AP/PA 'I did consume a lot of the reporting on the Holmes case because I found it so fascinating and poignant, particularly on issues of gender, how we portray women in the media, especially powerful women who make mistakes.' Taylor's path from growing up as the only child of a dairy farmer in rural Maine to taking a double degree at Harvard to becoming a sought-after debut author about to embark on a legal career is remarkably grounded. 'I had a pretty idyllic, rural childhood. I rode horses and worked on the farm in the summers, milking cows. But I was also very invested in school and I played a lot of sports and I had access to lots of great opportunities.' Her decision to go to Harvard was motivated by the pursuit of academic excellence, but when she arrived on campus, she felt out of place. 'That transition was pretty jarring, which is something that comes out in the novel. I didn't realise the extent to which most people at Harvard would have already been embedded in that sort of community of people who will go to Harvard. There are lots of ways that you can be in that pipeline, so I'm not talking about legacy or family connections, but people had gone to the same summer camps, or done the same competitive academic things like debate or math olympiad, or they had played sports together, and I truly had no connection to the institution at all, so when I showed up on campus for the admitted students weekend it was like everyone else already had friends and they knew how to act and they knew where things were and what parties were going on, and I was like how am I already not a part of this? " Her choice of degree – chemistry – reinforced that feeling of being an outsider. 'I was convinced I needed to do something practical with my college time. There were lots of people questioning my decision to even go to Harvard. I think this is really common in rural areas actually. You can go for free to your state university so people are like, why would you choose to go to this elite university that feels very other to our community, particularly when you're going to be paying an amount of money, that seems silly? That divide and that perception is only worse now, given all of the things that are going on in America. I think that and coming from a farming family gave me this fixation that I needed to do a hard science, be practical and have a skill.' When she took some English classes, it reignited her childhood love of writing. 'If you had asked me when I was 10, 'what do you want to be when you grow up?', I would have said 'writer'…but I came to realise that was a not a particularly stable or likely career path. In fact, I think it seemed like a total pipe dream, so I turned away." After college, she worked for a non-profit in New York for a year before returning to her family home to take a year out in an attempt to recover from debilitating migraines. 'I had some time and I thought, what I've actually always wanted to do was to be a writer, so let me try.' But it wasn't all smooth sailing. She wrote a novel, and submitted it to publishers but couldn't find a home for it. 'Which was very upsetting,' she says. But even as that first novel was dying on submission, she had already moved on to Notes On Infinity . Where did she find the determination to push on with another book in the face of that early rejection? 'I think it was mostly that I was really compelled by the idea for Notes. And I was really convinced that it could be special. Then there was a degree of stubbornness, which is part of my personality for better or for worse, and also a degree of naivety, which was necessary for me to do the whole thing. I think if I had thought too hard about how likely any of this was to work out, I simply wouldn't have done it because the odds are so low.' [ Pat O'Connor: 'Why would girls study Stem if they have no career path afterwards?' Opens in new window ] The book deals – in addition to the American deal, the book has sold for six figures in the UK, and at auction in Germany – have changed her life, she says. They've given her the time and space to get better at writing, although she says she has not yet touched any of the money. 'I don't think I've ever had a phone call where there was a 'you-should-sit-down' moment. Even the first payments are more money than I've ever seen in one place, ever.' She is planning on working as an attorney with an interest in the interface between AI and media and arts. 'I recognise we must make space for AI's vast potential but, as a firm believer in the power and importance of good storytelling, I am concerned that existing legal frameworks provide inadequate protection for writers and the publishing ecosystem.' She has no plans to stop writing – a double concentrator in life too, it seems. In fact she has already finished a draft of her second novel, which will centre around a similar subculture of very powerful young male tech founders and a young woman's relationship with an older, more professionally powerful man. But she is very excited to be going to Stanford – to study law, and for the weather too, which is balmier than the northerly climes she is used to, but also for another reason … 'I've started drafting my third novel…" she says. 'And it's going to be set in Silicon Valley.' Notes on Infinity by Austin Taylor is published by Michael Joseph.
Irish Times
6 days ago
- Irish Times
Genetic cures on demand: `Within four weeks, the vision in his eyes had doubled'
This year may prove to be an important year for advances in gene editing and gene therapies. But what does that really mean, and how have we got to this point? In what is claimed as a world first, doctors in the United States recently treated a baby with a rare genetic disease using a highly specific and personalised gene-editing technique . What did this involve and how is the baby doing? Baby boy KJ was born with a rare metabolic disease known as CPSI deficiency. This prevented his body from getting rid of ammonia during the metabolism of protein. And while he was put on a highly restricted protein diet and given drugs to remove protein from his blood, he remained at high risk of brain damage or even death. READ MORE Following the early diagnosis of KJ's condition, gene-editing researchers at the University of Philadelphia worked with colleagues throughout the US to quickly develop a personalised gene-editing infusion to correct a genetic variant that led to the disorder. KJ responded well to the three-dose regimen and is now reaching his developmental milestones. 'Ultimately, we hope this has set a precedent where we have firmly entered a world of genetic cures on demand,' said Fyodor Urnov, scientific director of the Innovative Genomic Institute in the University of California, Berkeley, a member of the treatment team. Have similar gene-editing techniques been used on patients in Ireland too and how do they differ from gene therapy? The gene-editing platform known as Crispr is widely used by researchers in scientific laboratories in their search for new therapies for cancer and other diseases. Essentially, Crispr – whose inventors won the Nobel Prize in chemistry in 2020 – is a cheap and efficient way of finding and altering specific pieces of DNA within cells. Clinical trials of gene therapies for inherited eye conditions are desperately needed for the treatment of an estimated 5,000 patients on the island of Ireland affected by these diseases — Dr Emma Duignan Gene therapy is slightly different in that it introduces new DNA materials into cells to replace or correct a gene or inactivate a target gene in the treatment of a specific disease. Earlier this year, ophthalmologic surgeon Dr Max Treacy treated 20-year-old Maros Tomko, who had severe visual loss since birth, with gene therapy at the Royal Victoria Eye and Ear Hospital in Dublin. The once-off treatment replaced the faulty gene RPE65 with a healthy copy. This was done via a viral vector which carried the healthy copy of the gene into the cells of the eye. 'Within four weeks, the vision in his eyes had doubled. From not being able to see any letters, he could read the first and second lines. His visual field [the total area seen] also doubled in size,' explains ophthalmologist Dr Emma Duignan. Tomko adds that he is very grateful to the doctors for this opportunity to have surgery. 'I can see people's faces now and I can read the numbers on my bank card for the first time. It's only three months since the surgery so it will take longer to get better,' he says. Ophthalmologist Dr Emma Duignan A 31-year-old Sligo man with a similar congenital blindness got his sight back after being treated with ocular gene therapy at the Mater hospital in Dublin in 2024. Gene therapies, however, remain very expensive and the Royal Victoria Eye and Ear Hospital treatment, which was paid for by the Health Service Executive, cost close to €800,000. Dr Duignan says it took years for the team to get the funding in place, but such treatments now mean that Dublin will have two potential centres for gene therapy clinical trials. 'Clinical trials of gene therapies for inherited eye conditions are desperately needed for the treatment of an estimated 5,000 patients on the island of Ireland affected by these diseases,' says Dr Duignan. Drugs used in clinical trials are made available free of charge. Manipulating human DNA – the genetic material responsible for life – is like the stuff of science fiction. How is it even possible? Research into gene therapy goes back to the 1940s and 1950s. The first studies began to recognise that DNA was a transforming substance capable of changing the living characteristics of individuals through a biochemical process. Later, studies identified that human stem cells (mainly found in the bone marrow) could be genetically modified to carry therapeutic DNA which could then differentiate into various cell types to correct genetic defects. In the 1980s, researchers at Boston Children's Hospital published a paper to show a virus could be used to insert genes into blood-forming stem cells. These so-called viral vectors later became an established way to deliver specific genetic material to human cells. In the meantime, the Human Genome Project was completed in 2003, paving the way for gene therapy to become a reality for multiple diseases, especially those caused by mutations in a single gene. What specific diseases are we talking about? The painful and life-threatening sickle cell disease, a rare genetic immune deficiency disorder called chronic granulomatous disease, and the rare childhood disease adrenoleukodystrophy have all been treated with gene therapy. Genetic diseases including cystic fibrosis , muscular dystrophy, sickle-cell anaemia and haemophilia could potentially be treated with gene therapy. But are there risks to making such precise changes to the basic building blocks of life? Yes, there are huge risks, which is why it has taken so long for gene therapy to reach clinical settings. In 1990, four-year-old Ashanthi de Silva became the first patient to be successfully treated with gene therapy. She was given a healthy adenosine deaminase (ADA) enzyme to cure the severe immunodeficiency disorder caused by the absence of ADA. Although she continues to take a drug to keep her condition under control, she leads an active life to this day. [ Delving into the power of DNA for patients Opens in new window ] Throughout the 1990s, European researchers focused on other forms of severe immunodeficiency disorders, reporting the first cures in 2000. However, some years later, five of the 20 treated children developed cancer. The viral vector which had delivered the gene to their T cells (immune cells in the body) had also activated an oncogene, triggering leukaemia. Also in the US, an 18-year-old boy died after receiving gene therapy for a rare metabolic disorder. These incidents delayed research into gene therapy for almost 10 years. But in the early 2010s, scientists developed better viral vectors that could more precisely target expressions of genes in specific cell types which don't go astray in the body and don't trigger an immune response. This spurred further developments in genetic therapies and several gene therapy drugs were approved for use. The use of messenger RNAs (mRNAs) – as was used in Covid-19 vaccines – also represents a form of gene therapy. In this case, the mRNA vaccine introduces information that cells then use to make the coronavirus spike protein, which then stimulates the person's immune system to develop antibodies to the virus. What are the next steps for gene editing and gene therapy? There are now hundreds of active gene therapy studies around the world and more than a dozen gene therapy drugs on the market, according to researchers at Boston Children's Hospital. A more finely tuned approach called base-editing, which uses Crispr technology to chemically change one 'letter' of a gene's code at a time, is deemed to be the next technological advance in genetic therapies. The small changes of base-editing can correct a 'spelling error' mutation, silence a disease-causing gene or help activate a specific gene. However, while this approach hasn't yet been tested in clinical trials, places such as Boston Children's Hospital have several base-editing projects under way. Dr Duignan adds that new so-called gene agnostic therapies, which will treat diseases caused by different gene mutations without having to develop a specific infusion for each mutation, represent the next frontier in gene therapy.
